The Impact of Lorazepam on Cognition in APOE e4 Carriers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00586430 |
Recruitment Status
:
Completed
First Posted
: January 4, 2008
Last Update Posted
: January 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer's Disease | Drug: lorazepam Drug: placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Screening |
Official Title: | The Impact of Lorazepam on Cognition in APOE e4 Carriers |
Study Start Date : | December 2005 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | July 2007 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
single 2 mg dose of lorazepam
|
Drug: lorazepam
single 2 mg dose of lorazepam
Other Name: Ativan
|
Placebo Comparator: 2
single dose of placebo
|
Drug: placebo
single dose of placebo
|
- Groton Maze Learning Task [ Time Frame: baseline, 2.5 hours and 5 hours ]
- Auditory Verbal Learning Test [ Time Frame: baseline, 2.5 hours and 5 hours ]
- 1-back test [ Time Frame: baseline, 2.5 hours and 5 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- a score of at least 28 on the MMSE
- a score of less than 10 points on the HAM-D-17
- age 50-65
- genotype APOE e3/e4 or APOE e4 non-carriers
- cognitively normal
Exclusion Criteria:
- significant medical, psychiatric, or neurological illnesses
- use of benzodiazepines within the previous four weeks
- currently using sedating antihistamines

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586430
United States, Arizona | |
Mayo Clinic | |
Scottsdale, Arizona, United States, 85259 |
Principal Investigator: | Cynthia M Stonnington, M.D. | Mayo Clinic |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Cynthia Stonnington, M.D., Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00586430 History of Changes |
Other Study ID Numbers: |
929-05 |
First Posted: | January 4, 2008 Key Record Dates |
Last Update Posted: | January 4, 2008 |
Last Verified: | December 2007 |
Keywords provided by Mayo Clinic:
apolipoprotein E e4 Alzheimer's disease somnolence Early detection |
Additional relevant MeSH terms:
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Lorazepam Anticonvulsants Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Hypnotics and Sedatives Central Nervous System Depressants Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |